Role of contrast-enhanced spectral mammography in the assessment of residual disease following neoadjuvant chemotherapy in patients with breast cancer

Egyptian Journal of Radiology and Nuclear Medicine

Table 4 Treatment response to NAC by CESM and histopathology according to pathological type

Pathological response to NAC	IDC (n = 116)		ILC (n = 14)		Mixed IDC/ILC (n = 6)		IMC (n = 4)		IPC (n = 2)
Pathological response to NAC	CESM	HP	CESM	HP	CESM	HP	CESM	HP	CESM	HP
CR	22	16	4	4	2	2	0	0	0	0
Non-CR	94	100	10	10	4	4	4	4	2	2

NAC neoadjuvant chemotherapy, IDC, invasive duct carcinoma, ILC invasive lobular carcinoma, IMC invasive medullary carcinoma, IPS invasive papillary carcinoma, n number, CESM contrast-enhanced spectral mammography, HP histopathology, CR complete response